Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trazodone once‑daily for major depressive disorder in women with breast cancer
2021-005007-12Phase 4Terminated
- Sponsor
- Angelini Pharma
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of trazodone hydrochloride prolonged-release tablets in major depressive disorder (MDD), sponsored by Angelini Pharma. Primary endpoint: Change in MADRS total score from baseline to week 12. Started Nov 2022; status: terminated.
02
Drugs
trazodone hydrochloride prolonged-release tablets
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2021-005007-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005007-12.